Our DNA acts like a book of recipes for making proteins. But if a recipe is wrong, what does a cell do Peng Mao, PhD, and his team discovered an intricate series of events that cells use to repair our DNA as the recipes are being read. Their findings could lead to improved cancer treatments.
Michaela A. Dinan, PhD, has been appointed Co-Leader of the Cancer Prevention and Control Research Program at Yale Cancer Center.
In a new article published in Clinical Cancer Research, Moffitt Cancer Center researchers describes the immune-oncologic differences in prostate cancer tumors of African American men and how those variations may be exploited to develop more personalized treatment approaches for this population.
The University of Texas MD Anderson Cancer Center will host the fifth annual Boot Walk to End Cancer® virtually on Saturday, Nov. 7. The virtual walk will take place online and in neighborhoods across the country in an effort to keep participants, their families and their communities safe and as part of MD Anderson's commitment to prioritizing the health and safety of patients, workforce members and the greater Houston community.
The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an oncology-focused investment fund designed to support the advancement of compelling investigational cancer therapies from late preclinical development through Phase I and Phase Ib/II clinical trials.
Two prominent early intervention models for toddlers with autism show a very similar impact, whether delivered at 15-hours or 25-hours per week intensities, a study led by UC Davis MIND Institute researchers has found.
With specialized knowledge about medications and how they work to fight cancer, oncology pharmacists and pharmacy technicians play a vital role in patient care and research.
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.
In a new article published in Nature Communications, Moffitt Cancer Center researcher demonstrate how a deep learning model using positron emission tomography/computerized tomography radiomics can identify which non-small cell lung cancer patients may be sensitive to tyrosine kinase inhibitor treatment and those who would benefit from immune checkpoint inhibitor therapy.
After more than two years of reconstruction efforts, scientists from the Fred Hutchinson Cancer Research Center have moved into their new labs at the newly renovated Lake Union Steam Plant.
MD Anderson and Allogene today announced a strategic five-year collaboration for preclinical and clinical investigation of allogeneic CAR T cell therapies.
In a new article published in the journal Nature Communications, Moffitt Cancer Center researchers describe how the protein TAp63 controls levels of RNA molecules, which subsequently connects the activities of p53 and AKT to promote disease progression.
The NCCN Oncology Research Program (ORP) plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2), supported by a $2-million grant from Puma Biotechnology, Inc.
A new study by the UC Davis Violence Prevention Program looked at the intersection of the coronavirus pandemic and violence-related harms in California. It found that COVID-19 pandemic was linked to an estimated 110,000 firearm purchases in California and increases in individuals’ worries about violence.
Karen E. Knudsen, MBA, PhD, is the new president of the Association of American Cancer Institutes (AACI). Dr. Knudsen is enterprise director of Sidney Kimmel Cancer Center at Jefferson Health in Philadelphia.
In a new COVID-19 clinical trial, Stuart Cohen at UC Davis Health evaluates the efficacy, safety and tolerability of monoclonal antibody combination in adults exposed to patients with COVID-19. It is the same antibody drug given to President Trump to treat his COVID-19.
A new, residential four-year college program for students with intellectual disabilities is the first of its kind in the west and is expected to serve as a model for other California schools.
Phase I trial finds neoadjuvant combination checkpoint inhibitors (anti-CTLA-4 plus anti-PD-1) was well tolerated and showed early signs of activity in certain patients with bladder cancer. These patients cannot be treated with chemotherapy and have no standard treatment options available.
The Rutgers Youth Enjoy Science (RUYES) program, funded by the National Cancer Institute, will engage underrepresented minority undergraduate and high school students in cutting-edge cancer research, curriculum support, and professional development activities.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right